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Abstract
Objective—Since HIV impairs gut barriers to pathogens, HIV-infected adults may be vulnerable 
to Minimal Hepatic Encephalopathy (MHE) in the absence of cirrhosis.
Background—Cognitive disorders persist in up to one-half of people living with HIV despite 
access to combination antiretroviral therapy (cART). MHE occurs in cirrhotic patients with or 
without HIV infection and may be associated with inflammation.
Design/Methods—A cross-sectional investigation of liver fibrosis severity using the aspartate 
aminotransferase to platelet ratio index (APRI) and neuropsychological testing performance 
among women from the Women’s Interagency HIV Study (WIHS). A subset underwent liver 
transient elastography (FibroScan®, n=303).
Results—We evaluated 1479 women (mean (SD) age of 46 (9.3) years): 770 (52%) only HIV-
infected, 73 (5%) only HCV-infected, 235 (16%) HIV/HCV co-infected, and 401 (27%) 
uninfected. Of these, 1221 (83%) exhibited APRI ≤0.5 (no or only mild fibrosis), 206 (14%) 
exhibited APRI >0.5 and ≤1.5 (moderate fibrosis), and 52 (3%) exhibited APRI >1.5 (severe 
fibrosis). Having moderate or severe fibrosis (APRI >0.5) was associated with worse performance 
in learning, executive function, memory, psychomotor speed, fluency, and fine motor skills. In 
these models that adjusted for fibrosis, smaller associations were found for HIV (learning and 
memory) and HCV (executive functioning and attention). The severity of fibrosis, measured by 
FibroScan®, was associated with worse performance in attention, executive functioning, and 
fluency.
Conclusions—Liver fibrosis had a contribution to cognitive performance independent of HCV 
and HIV; however, the pattern of neuropsychological deficit associated with fibrosis was not 
typical of MHE.
Keywords
HIV; Liver diseases; AIDS Dementia Complex; Cognition; Cirrhosis; Minimal Hepatic 
Encephalopathy
INTRODUCTION
Hepatic encephalopathy (HE) due to cirrhosis is characterized by broad cognitive deficits 
including psychomotor retardation, impairment of memory, and deficits in concentration.1 
The pathogenesis of HE is thought to arise from astrocyte dysfunction due to excess levels 
of ammonia and other toxins, with added contributions from inflammation.2 Since astrocytes 
are involved in ammonia clearance through conversion of glutamine to glutamate, it is 
postulated that glutamine build-up leads to osmotic imbalance, cellular swelling, and 
astrocyte dysfunction.
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An entity of “subclinical” hepatic encephalopathy was first defined in 1978, occurring in 
cirrhotic patients who appeared normal but had measurable neuropsychological test 
abnormalities.3 This condition, later termed Minimal Hepatic Encephalopathy (MHE), 
occurs intermittently in up to two-thirds of patients with cirrhosis.4 In these patients who 
lack obvious encephalopathy, subtle cognitive dysfunction may intermittently impact daily 
activities including driving.5,6 Commonly observed deficits in neuropsychological testing 
involve psychomotor speed, information processing, and attention or vigilance.7,8 It is 
typically a diagnosis of exclusion among individuals with chronic liver disease as there are 
no diagnostic tests to confirm MHE.
Precipitating factors for MHE include those that burden liver processing such as 
gastrointestinal bleeding, alcohol use, infection, portal vein thrombosis, dehydration, and 
renal failure.9 These triggers putatively add inflammation and toxins or decrease clearance 
of toxins that can impact the central nervous system (CNS). The pattern of 
neuropsychological deficits seen with MHE overlaps with that described among patients 
living with chronic HIV infection with both conditions characterized by fluctuation and 
including impaired executive function.10,11 Together, this information provides a rationale 
for evaluating the independent contributions of liver fibrosis in the setting of HIV. The 
Women’s Interagency HIV Study (WIHS) offers a unique opportunity to test this hypothesis 
in a population with substantial hepatitis C virus (HCV) co-infection.
We hypothesized that both the inflammation associated with chronic HIV infection and the 
HIV-associated loss of intestinal gut protective barriers resulting in gut microbial 
translocation could add risk for MHE in patients with chronic HIV infection.12 If so, liver 
fibrosis, even in the absence of cirrhosis, would correlate with neuropsychological test 
performance, independent of HIV or HCV. Such a finding would add further support to 
shifting paradigms related to cognition in HIV where greater etiologic heterogeneity is 
emerging.13 These analyses are timely since neuropsychological testing impairment remains 
prevalent despite access to effective combination antiretroviral therapy (cART).
METHODS
Participant selection
The WIHS is a multicenter longitudinal observational cohort of HIV-infected and uninfected 
women enrolled from one of six U.S. sites: New York (Bronx and Brooklyn), California 
(Los Angeles and San Francisco), Washington DC, and Chicago.14 At the time of enrollment 
into WIHS, participants were free of known dementia and able to attend an outpatient study 
visit. All signed Institutional Review Board-approved consent forms.
An extended neuropsychological testing battery was added to the WIHS exam in 2009 with 
all testing completed by April 2011. Of the active English-speaking participants (n=1,908), 
1,595 (84%) completed the test battery of whom 1547 had concurrent blood work to 
calculate the fibrosis marker and the necessary key covariates. We included 1479 
participants (1005 HIV-infected) in the analysis after excluding 68 participants meeting one 
or more of the following exclusion criteria: a) conditions that limit test validity (e.g., hearing 
loss, impaired vision, immediate influence of illicit substances, n=11); b) history of stroke 
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(n=10); and c) self-reported use of antipsychotic medication in the previous 6 months 
(n=47).
Cognitive characterization
The neuropsychological battery was designed to capture domains impacted by HIV 
infection.10 A global score of all cognitive tests served as one primary outcome. To 
minimize the effect of multiple comparisons, we looked at domain scores first and explored 
individual tests within domains chiefly when the domain score was significant. We also 
identified primary and secondary outcomes a priori. Individual tests allowed us to evaluate 
seven cognitive domains, including four also used as primary outcomes based on existing 
data linking them to MHE: (1) Verbal Learning [Hopkins Verbal Learning Test (HVLT) Trial 
1 (single trial learning) and HVLT Total Learning (total words recalled across each of three 
learning trials)]; (2) Attention and Concentration [Stroop Trials 1 and 2 (average time to 
complete each trial), Trail Making Test Part A (time to complete), and control condition 
from Letter Number Sequencing (LNS) (total correct)]; and (3) Executive Function [Stroop 
Trial 3 (time to completion), Trail Making Test Part B (time to complete), and working 
memory condition of LNS (total correct)]. Secondary outcomes were those not describe to 
be linked to MHE and include: (1) Verbal Memory [HVLT delayed recall (total words 
recalled after 25-minute delay) and percent retention (delayed recall/maximum score on 
Trial 2 or 3)]; (2) Psychomotor Speed [Symbol Digit Modalities Test (total number correct 
within 90 seconds)]; (3) Verbal Fluency [Letter Fluency (total words generated in response 
to the letters F, A, and S) and a Category Fluency Task (total words generated in response to 
the category of animals)]; and (4) Fine Motor Skills [Grooved Pegboard Test (average time 
to complete dominant and non-dominant hands)]. All testers were internally certified 
through structured training and quality assurance. We used the Wide Range Achievement 
Test (WRAT-3) to estimate education quality.
Clinical variables
We confirmed HIV status with FDA-approved enzyme-linked immunosorbent assays and re-
confirmed with western blot assays when immunosorbent assays were positive. Chronic 
hepatitis C infection was defined using HCV antibody testing from each woman’s 
enrollment visit into the WIHS and with subsequent confirmatory HCV RNA testing, when 
available. Women were classified as HCV-uninfected if the HCV antibody was negative or if 
the HCV RNA level was undetectable among those with positive HCV antibody. Participants 
who were HCV antibody positive with detectable HCV RNA were coded as HCV-infected. 
Those with untested HCV RNA (n=30) were also coded as HCV infected, since spontaneous 
clearance of HCV is uncommon in the setting of HIV infection and since HCV treatment 
and cure was uncommon during this calendar time frame. Other variables included in the 
analysis and measured concurrently with the cognitive testing included heavy alcohol use, 
defined as reporting >7 drinks per week or more than 4 drinks in one sitting, and 
hypertension, defined as having a systolic blood pressure >140 mmHg, diastolic blood 
pressure > 90 mmHg, or self-reported use of anti-hypertensive medications.
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Definition of Liver Fibrosis
The aspartate aminotransferase to platelet ratio index (APRI) is an indirect serum fibrosis 
marker combining standard laboratory tests ((AST/upper limit of normal AST)*100)/platelet 
count). APRI has been studied in large cohorts of HIV-mono-infected, HCV-mono-infected, 
and HIV/HCV-co-infected patients and can be used to distinguish mild fibrosis from 
significant fibrosis and cirrhosis.15,16 We categorized APRI using validated cutoffs: ≤0.5 
(mild or no fibrosis); >0.5 to ≤1.5 (moderate fibrosis); and >1.5 (severe fibrosis). For our 
analyses, moderate and severe fibroses were combined as significant fibrosis (i.e. at least 
moderate fibrosis) since the sample size for severe fibrosis was small (n=52).
In a separate study embedded from three sites in the WIHS (Chicago, San Francisco and 
DC), 381 women underwent transient elastography (FibroScan®, Echosens, Paris, France) to 
estimate liver fibrosis by measuring liver stiffness by ultrasound, of which 315 had valid 
readings within 6 months of neuropsychological testing.17 We again excluded participants 
for one or more of the following criteria: a) conditions that limit test validity (e.g. hearing 
loss, impaired vision, or immediate influence of illicit substances, n=1); b) history of stroke 
(n=11); and c) self-reported use of antipsychotic medication in the past 6 months (n=1) 
resulting in 303 evaluable FibroScan®-neuropsychological testing pairs. Due to FibroScan® 
timing, many cases were completed concurrently with the second (n=140; 46%) and third 
(n=22; 7%) time a participant underwent comprehensive neuropsychological testing.
Statistical analyses
Given the absence of published cognitive norms for low-income minority women, we 
followed Heaton et al. (1991) and prior work in the WIHS, using a regression-based 
approach to create demographically corrected normative standards (T-scores) based on a 
larger sample of HIV-uninfected WIHS women (n=502).18–23 Simply, we used a regression 
approach to estimate premorbid levels of function for the total sample based on scores of the 
comparison group (HIV women). Each outcome was first regressed on age, years of 
education, Reading Recognition subtest from the Wide Range Achievement Test-Revised 
(WRAT-R), a proxy for educational quality, and race/ethnicity.22 The resulting 
unstandardized beta weights, constants, and standard errors were used to calculate predicted 
scores for each test that were then subtracted from each woman’s actual score and 
transformed to scores (using means of 50 and standard deviations of 10) that could be more 
easily compared across all cognitive outcomes. The Trail Making, Stroop, and Grooved 
Pegboard scores were skewed and therefore log-transformed prior to the creation of the T-
scores.
We examined demographic characteristics by fibrosis status using t-tests for continuous 
variables and Chi-square tests for categorical variables. The Breslow Day test was used to 
compare whether the proportion of women with significant fibrosis differed as a function of 
both HIV and HCV status. We used multivariable linear regression to determine if liver 
fibrosis was associated with neuropsychological test performance (i.e. global performance 
and domain specific performance), independent of HIV and chronic HCV. In order to 
minimize false discoveries, we defined primary outcomes (see above) and considered 
associations of individual test scores (T-scores) within these domains as more exploratory. 
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Additional multivariable linear regression models were conducted, as needed, to determine 
the stability for specific subsets of women (e.g. HIV mono-infected).
In the FibroScan® sub-analysis, we investigated each neurocognitive test since this analysis 
was conceived of as a confirmatory analysis of our primary APRI analysis. The models 
adjusted for important potential confounders including marijuana use, crack/cocaine and/or 
heroin use, smoking, heavy alcohol use, antidepressant use, annual household income, body 
mass index, hypertension, diabetes, study site, and number of previous cognitive test 
exposures. The FibroScan® readings were log transformed. Significance was defined as 
p<0.05 (two-sided). Analyses were performed using SAS PROC GENMOD (version 9.4, 
SAS Institute Inc., Cary, NC).
RESULTS
The final sample included 1,005 HIV-infected and 474 HIV-uninfected women with mean 
age of 47 and 44 years (p<0.001), respectively; 64% were African American. Women with 
significant fibrosis had a higher BMI (p<0.001) and other metabolic risk factors such as 
hypertension and diabetes (Table 1). They also had worse HIV parameters, such as having a 
lower proximal and nadir CD4 count and detectable plasma HIV RNA.
Significant fibrosis was noted in 258 (17%) of which 206 had moderate fibrosis and 52 had 
severe fibrosis. The proportion with significant fibrosis differed as a function of both HIV 
and HCV status (Breslow Day Test, p=0.02, Figure 1). Among HCV-infected women, also 
having HIV increased the odds of significant fibrosis (OR 4.79 95%CI 2.46–9.33, p<0.001). 
Among HCV-uninfected women, the same pattern was noted but the magnitude of the 
association was attenuated (OR 1.77 95%CI 1.04–3.00, p=0.03).
The association of significant liver fibrosis was demonstrated across numerous primary and 
secondary outcome measures (Table 2). Specifically, we found independent associations 
between significant fibrosis and executive functioning (primary outcome) and for verbal 
memory, psychomotor speed, fluency and fine motor skills (secondary outcomes). Within 
the executive functioning domain, the primary outcome domain meeting our threshold of 
significance, only the Stroop trial 3 differed. To explore the degree to which co-infection 
(HCV and HIV) drove our findings, we ran a series of separate multivariable models 
including only HIV mono-infected women (n=770). These models identified more limited 
effects between significant fibrosis and psychomotor speed (B=−2.81, SE=1.10, p=0.01) and 
a trend for effect on the global neuropsychological test (B=−1.12, SE=0.65, p=0.08).
We also evaluated the independent contributions of HIV and HCV to cognitive functioning 
in a model that included fibrosis plus key confounding variables (Table 3). As in our primary 
model, liver fibrosis (B=−1.22, SE=0.45, p=0.007) was independently associated with the 
omnibus global neuropsychological composite score of all neuropsychological tests where 
women with significant liver fibrosis had lower scores compared to women without 
significant fibrosis (Cohen’s d=−0.24, 95% CI −0.39 to −0.09). However, HCV did not have 
independent associations on any of our primary or secondary cognitive domain scores; 
although associations were noted for two individuals test scores (Stroop 1 & 2 and Trail 
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Making B). HIV status was associated with both the verbal learning and verbal memory 
domain score, as previously described.18
We evaluated liver fibrosis as measured by FibroScan® for 303 women. Fibrosis was 
associated with two of our secondary domain scores (fluency and fine motor skill, Table 4). 
Although not associated with the primary domain scores, fibrosis was associated with 
individual test scores in other primary and secondary domains (attention & concentration, 
executive functioning, and verbal memory). In models adjusted for HCV and HIV, fibrosis 
remained associated with the fluency domain and with several tests in the executive 
functioning and attention & concentration domains.
In exploratory analyses, we investigated interactions between HIV status and liver fibrosis 
on cognition finding that liver fibrosis interacted with HIV status to influence fine motor 
skills (p=0.020). This interaction was in a counterintuitive direction, such that among HIV-
uninfected women, women with significant fibrosis performed worse on fine motor skills 
than did women without significant fibrosis. However, among HIV-infected women, there 
was no difference in performance between women with and without significant fibrosis. 
When we explored interaction effects between HCV and fibrosis, we noted an effect on the 
executive functioning domain where, among HCV+ women, women with significant fibrosis 
performed worse than women without significant fibrosis (B=−3.00, SE=1.05, p=0.004). 
Among HCV− women, women with significant and not significant fibrosis performed 
similar (B=−0.17, SE=0.90, p=0.85). The same significant interaction was seen on both Trail 
Making Test Part B (p=0.020) and on the Delayed free recall portion of the HVLT 
(p=0.040). Trends for interactions were noted on LNS working memory (p=0.060) and 
semantic fluency (p=0.06). These were deemed exploratory since sample size for HCV− 
women with significant fibrosis was only 94.
DISCUSSIONS
Findings from this study provide evidence for an alternative mechanistic pathway of 
cognitive dysfunction in patients living with HIV as a chronic illness regardless of access to 
cART, a finding that is most important for HCV dual-infected individuals since they have the 
highest burden of fibrosis. We find that significant liver fibrosis, as measured by APRI, is 
associated with worse neuropsychological testing performance and that these associations 
are independent of both HIV and HCV. Together, these data buttress the contention that 
cognitive dysfunction represents a set of factors that converge in chronically infected 
patients.
Our findings are unlikely due to cirrhosis alone since most cases with “significant” fibrosis 
had an APRI score < 2 (217/258, 84%) a threshold previously linked to cirrhosis.15 We did 
not have sufficient cases with APRI >2 to include this as a separate analysis. Although not 
meeting statistical significance, the beta coefficients for the impact of APRI in both 
moderate and severe degrees of fibrosis were in the same direction. The identified 
associations despite less severe fibrosis would support the hypothesis that patients with HIV 
are at higher risk for MHE; however, the pattern of cognitive impairment identified here is 
not typical of that described in MHE. This raises suspicion that mechanisms may not fully 
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overlap. The role of inflammation cannot be excluded either since both fibrosis and 
cognitive impairment have been linked to this common mechanism. Combining measures of 
gut permeability with that of fibrosis could be informative.
In a sub-sample of participants, our APRI analyses are bolstered by ultrasound measures of 
fibrosis using FibroScan®, which has an area under the curve (AUC) of 0.81 for predicting 
significant fibrosis based on biopsies among patients with HCV.24 Although there is 
incomplete overlap regarding individual cognitive domains when compared to our main 
analyses, the beta coefficients are in the same direction and differences in significance may 
reflect smaller sample sizes. We used the APRI rather than fibrosis-4 (Fib-4) index, a second 
calculation of fibrosis involving serological measures available in this cohort. This 
strengthens our work since both the Fib-4 index and neuropsychological testing are strongly 
influenced by age. In contrast, age is not a factor of the APRI calculation.
In the era of cART, cognitive impairment in HIV more frequently involves tests that evaluate 
more complex cognitive function, including executive dysfunction.11,25 In a separate 
analysis from the WIHS, women were noted to have more prominent deficits in verbal 
memory than has typically been described in predominantly male cohorts.18 Not 
surprisingly, our analyses, which included approximately the same individuals as this prior 
WIHS study, broadly recapitulated these HIV-associated findings even when adjusted for 
fibrosis.
While HCV has a substantial impact on morbidity and mortality, the impact on cognition in 
the setting of HIV is less certain, in part owing to methodological differences, small sample 
sizes, and insufficient cognitive testing batteries.26–29 Limitations in everyday function 
associated with deficits in neuropsychological testing performance have been documented in 
co-infected participants.30 But one recent study (n=1582) including subjects enrolled at US 
academic centers noted no substantial differences in cognitive performance when comparing 
HCV infected and uninfected participants living with chronic HIV.31 Similarly, we find only 
limited effects of HCV in our cohort, but note substantial associations with liver fibrosis 
instead. This reinforces the idea that the degree of liver fibrosis is a more important predictor 
of cognitive performance than HCV status.
There have been two previous studies of HCV and cognition in the WIHS, each noting no 
effects of HCV in properly adjusted models.27,32 One evaluated a substantially smaller 
sample in which HCV-related findings did not withstand adjustment for age; the other relied 
upon an abbreviated neuropsychological testing battery. There are mixed reports on the use 
of plasma HCV RNA levels, with some identifying a predictive role among HCV mono-
infected patients, but others noting no association with HCV and HIV co-infected 
participants.26,33
The correlative nature of our study does not permit us to establish causal relationships, 
limiting this study. Our study is strengthened by a strict definition of chronic hepatitis C, 
which involves both antibody testing and RNA confirmation, therefore excluding most 
participants who cleared their infection. Other strengths include the size of the cohort and 
the extent of neuropsychological testing.
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Several clinical implications emerge from this work. First, our data note that an APRI >0.5 
may be a useful independent marker of risk for cognitive impairment, particularly among co-
infected patients. Second, we highlight the importance of fibrosis over simple serology as a 
marker of cognitive performance in HCV. Third, we provide evidence of contributions to 
cognitive impairment that are not HIV-specific in the current era, broadly expanding our 
understanding of the multifactorial determinants of cognitive impairment in patients with 
HIV.
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Figure 1. 
Proportion of women with significant fibrosis as a function of HCV and HIV status.
Note. The proportion of women with significant liver fibrosis differed as a function of both 
HCV and HIV status (Breslow Day Test, p<0.05).
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Table 3
Independent contributions of HIV and HCV controlling for significant fibrosis by APRI 
on cognitive test performance
Results from multivariable linear regression analyses of primary and secondary outcome measures.
Cognitive Domains n
Primary Predictors
HIV-infection
B (SE)
Hepatitis C positive
B (SE)
Primary Outcomes
 Verbal Learning 1467
−1.34 (0.53)* −0.02 (0.71)
  HVLT: Trial 1 1467
−1.46 (0.56)** 0.10 (0.75)
  HVLT: Total Trials 1–3 1467
−1.23 (0.56)* −0.13 (0.75)
 Attention and Concentration 1290 −0.83 (0.44) −0.50 (0.59)
  Stroop Trial 1&2 1456
−1.53 (0.64)* −2.58 (0.86)**
  Trail Making Test Part A 1465 −0.28 (0.58) 0.73 (0.78)
  LNS Attention 1305
−1.37 (0.63)* −1.03 (0.84)
 Executive Functions 1223 −0.06 (0.51) −0.66 (0.50)
  Stroop Trial 3 1407 −0.32 (0.75) −0.48 (0.73)
  Trail Making Test Part B 1427 −0.07 (0.60)
−1.76 (0.81)*
  LNS Working Memory 1270 0.03 (0.67) 0.43 (0.89)
Secondary Outcomes
 Verbal Memory 1467
−1.45 (0.53)** 0.94 (0.71)
  HVLT: Delayed free recall 1467
−1.57 (0.56)** 0.78 (0.79)
  HVLT: Percent Retention 1467
−1.33 (0.58)* 1.13 (0.77)
 Psychomotor Speed 1459 −0.26 (0.56) −0.28 (0.75)
 Fluency 1458 0.19 (0.49) 0.46 (0.66)
  Letter 1460 0.36 (0.59) 0.35 (0.79)
  Semantic 1458 0.07 (0.57) 0.60 (0.76)
 Fine Motor Skills 1416 0.18 (0.59) −0.30 (0.79)
  Dominant hand 1444 0.37 (0.60) −0.60 (0.80)
  Non-dominant hand 1416 −0.11 (0.63) −0.12 (0.84)
Note.
***p<0.001;
**p<0.01;
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*p<0.05.
HVLT = Hopkins Verbal Learning Test; LNS = Letter-Number Sequence; B = parameter estimates; SE= Standard Errors. All models are adjusted 
for APRI, site, marijuana use, crack, cocaine, and/or heroin use, smoking, heavy alcohol use, antidepressants, depressive symptoms, body mass 
index, hypertension, diabetes, income, and number of previous cognitive test exposure.
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